While Johnson & Johnson (NYSE: JNJ) celebrates success with its novel depression therapy Spravato (esketamine), hopes for Allergan’s (NYSE: AGN) innovative option rapastinel were struck a blow on Wednesday.
The firm had hoped to rival Spravato with a better safety profile, but negative results from three pivotal studies show the candidate is lacking in efficacy.
Shares in Allergan fell by 2.5% in post-market trading Wednesday, but recovered to $144.20 today.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze